BMRN

BioMarin Pharmaceutical Inc.

75.56 USD
+0.04 (+0.05%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioMarin Pharmaceutical Inc. stock is down -6.61% since 30 days ago. The next earnings date is Jul 29, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52% of the previous 24 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 May 15:01 16 Jan, 2026 75.00 PUT 90 10
16 May 15:13 20 Sep, 2024 90.00 CALL 200 2207
17 May 15:15 19 Jul, 2024 80.00 CALL 187 43
17 May 15:16 19 Jul, 2024 80.00 CALL 310 43
17 May 17:40 20 Sep, 2024 90.00 CALL 500 2105
17 May 18:42 17 Jan, 2025 75.00 PUT 66 327
17 May 19:10 17 Jan, 2025 75.00 PUT 67 327
17 May 19:37 17 May, 2024 50.00 CALL 10 10
17 May 19:39 19 Jul, 2024 80.00 PUT 84 518
20 May 14:10 19 Jul, 2024 80.00 CALL 157 547

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

  • Baird
    Fri May 17, 05:19
    hold
    downgrade
  • Evercore Partners
    Tue May 14, 05:10
    buy
    initial
  • Morgan Stanley
    Fri Apr 26, 12:38
    buy
    confirm
  • Canaccord Genuity
    Fri Apr 26, 08:47
    hold
    confirm